A topic in the Open Knowledge Graph — a free, open map of 15,290 topics and the order to learn them in.
Mast cells and basophils are tissue-resident and circulating granulocytes that bridge innate and adaptive immunity. Upon cross-linking of FcεRI by allergen-bound IgE, they rapidly release preformed granules containing histamine, tryptase, and heparin, followed by synthesis of lipid mediators (leukotrienes, prostaglandins) and cytokines. This orchestrated response defines immediate allergic reactions.
Study mast cell distribution across tissues and their role in homeostasis versus allergy. Compare immediate and delayed phases of allergic response.
Mast cell activation is not solely IgE-dependent—complement, substance P, and physical stimuli can also trigger degranulation. Mast cells serve protective roles in parasitic infections, not just harmful allergic reactions.
From your study of IgE signaling and type I hypersensitivity, you know that allergic reactions involve antigen cross-linking of IgE molecules bound to high-affinity Fc epsilon receptors (FcεRI). Mast cells and basophils are the effector cells that carry out this response, and understanding their biology explains not only why allergies produce the symptoms they do, but also why these cells evolved in the first place.
Mast cells are tissue-resident sentinels derived from bone marrow precursors that complete their maturation in peripheral tissues under the influence of stem cell factor (SCF) and local cytokines. They are strategically positioned at the body's interfaces with the environment — skin, airways, gastrointestinal mucosa, and around blood vessels — exactly where pathogens and allergens first make contact. Each mast cell is loaded with hundreds of preformed granules containing histamine, heparin, tryptase, chymase, and TNF-α, ready for immediate release. Basophils, by contrast, are circulating granulocytes that are far less abundant (less than 1% of white blood cells) but are recruited to tissues during allergic inflammation and share many functional features with mast cells, including surface FcεRI expression and histamine-containing granules.
The allergic response unfolds in two phases. The immediate phase (within seconds to minutes) begins when a multivalent allergen cross-links IgE molecules on adjacent FcεRI receptors, triggering receptor aggregation and a signaling cascade through Lyn and Syk kinases. This leads to rapid degranulation — the explosive release of preformed granule contents. Histamine binds H1 receptors on vascular endothelium, causing vasodilation and increased permeability (producing the redness, swelling, and wheal of an allergic reaction); on bronchial smooth muscle, it causes constriction (producing wheezing in asthma). Simultaneously, mast cells begin synthesizing lipid mediators from membrane phospholipids — leukotrienes (especially LTC4, LTD4, and LTE4, which cause prolonged bronchoconstriction far more potent than histamine) and prostaglandin D2 (which promotes vasodilation and neutrophil recruitment).
The late phase (4–8 hours later) involves newly synthesized cytokines and chemokines — IL-4, IL-5, IL-13, TNF-α, and various chemokines — that recruit eosinophils, basophils, and Th2 cells to the site. This sustained inflammation is responsible for the chronic tissue damage seen in conditions like allergic asthma and atopic dermatitis. Importantly, mast cells did not evolve to cause allergies. Their primary function is defense against helmintic parasites — large, multicellular organisms that cannot be engulfed by phagocytes. IgE-mediated mast cell degranulation at mucosal surfaces releases mediators that increase mucus secretion, enhance peristalsis, and recruit eosinophils, collectively working to expel the parasite. Allergic disease occurs when this parasite-defense system misfires against harmless environmental antigens like pollen, dust mite proteins, or peanut allergens — a misdirected immune response with the same molecular logic but a profoundly different clinical outcome.